Popular Trials
Virus Therapy
Lenacapavir for HIV Prevention
This trial is testing lenacapavir, a drug that may help prevent HIV. It targets people who are at risk of getting HIV. The drug works by stopping the virus from making more copies of itself. Lenacapavir was developed by Gilead Sciences Inc. and has been approved for use in combination with other treatments.
Nonsteroidal Anti-inflammatory Drug
Celecoxib +2 More for Cardiovascular Disease
The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.
Popular Filters
Trials for HIV/AIDS Patients
Growth Hormone Therapy for HIV/AIDS
This trial will study how a drug called recombinant human growth hormone affects the size of the replication competent HIV reservoir in people with HIV on stable antiretroviral therapy. 22 participants will take part for 52 weeks.
Trials for HIV Patients
Antiretroviral
E/C/F/TAF for HIV-1 Infection
This trial tests a single pill combining four HIV medications in adolescents and children. It aims to find the right dose and ensure safety for those new to treatment and those already on it. The pill works by stopping the virus from growing and spreading.
Phase 3 Trials
Antiretroviral
E/C/F/TAF for HIV-1 Infection
This trial tests a single pill combining four HIV medications in adolescents and children. It aims to find the right dose and ensure safety for those new to treatment and those already on it. The pill works by stopping the virus from growing and spreading.
Cephalosporin Antibiotic
Cefixime vs. Penicillin for Syphilis
This trial compares two antibiotics, cefixime taken by mouth and benzathine penicillin G given as an injection, to treat early syphilis. It includes patients with and without HIV to find an effective alternative to penicillin. The study aims to help those who are allergic to penicillin or affected by penicillin shortages. Cefixime is being tested as an alternative to penicillin for treating early syphilis, especially for those allergic to penicillin or during penicillin shortages.
Trials With No Placebo
Growth Hormone Therapy for HIV/AIDS
This trial will study how a drug called recombinant human growth hormone affects the size of the replication competent HIV reservoir in people with HIV on stable antiretroviral therapy. 22 participants will take part for 52 weeks.
View More Related Trials
Frequently Asked Questions
Introduction to aids
What are the top hospitals conducting aids research?
In the ongoing battle against AIDS, hospitals across the United States are making significant strides in clinical trials and research. Northwestern University, located in Chicago, is at the forefront of these efforts with three active AIDS trials and a cumulative total of four trials dedicated to this complex condition. Since conducting their first trial back in 1998, they have been committed to unraveling the mysteries surrounding AIDS.
Heading east to Boston, we find Boston Medical Center also contributing to groundbreaking research on HIV/AIDS. With three current clinical trials and a remarkable nine completed studies since their inaugural AIDS trial in 2009, this hospital plays a crucial role in advancing our understanding of this disease.
Meanwhile, down south in Orlando, Florida stands the Orlando Immunology Center—a leading institution focused on combating HIV/AIDS. This facility currently has two active clinical trials and an impressive tally of seventeen previously conducted studies since embarking on their first AIDS trial back in 2003.
Venturing westward to Bakersfield brings us to GSK Investigational Site—another key player engaged in critical HIV/AIDS research. With two ongoing AIDS trials and seventeen completed investigations dating back to their first recorded trial in 2004, this site exemplifies unwavering dedication towards finding effective treatment options for those affected by this devastating condition.
Lastly but certainly not least is Emory University situated within Atlanta's vibrant medical community. While relatively new compared to its counterparts mentioned earlier with its first recorded aid’s experiment starting only seven years ago; Emory University has nonetheless emerged as a formidable force with two current aids tests underway along with ten successfully concluded all-time projects; showcasing determined spirit prevalent among researchers here who are working tirelessly toward shaping future approaches for addressing aids while fostering hope for millions impacted worldwide
As these top hospitals continue pushing boundaries through relentless investigation into potential treatments and preventative measures for HIV/AIDS patients nationwide it becomes increasingly clear that when it comes conquering such complex conditions —where much work still lies ahead— collaboration among these leading institutions is key, offering a ray of hope to those affected by the disease and serving as a beacon for medical progress.
Which are the best cities for aids clinical trials?
When it comes to AIDS clinical trials, several cities emerge as key hubs for research and development. New york, with its 54 active trials, focuses on studies like Data to Suppression (D2S), Treatment variations, and Arm B: No anti-CMV treatment. San Francisco follows closely behind with 20 ongoing trials that delve into treatment approaches such as Oral Lenacapavir (LEN) in the Intervention Arm. Los Angeles also plays a significant role with 15 active trials exploring treatments like Cabotegravir - Injectable Suspension (CAB LA). Other notable locations include Boston, Massachusetts, where researchers are investigating different interventions including MVA-BN-HIV; and Chicago, Illinois which is involved in studies examining treatments like Oral Lenacapavir (LEN) and Cabotegravir - Injectable Suspension (CAB LA). These cities provide individuals affected by AIDS access to cutting-edge clinical trials that pave the way for advancements in care and improved outcomes.
Which are the top treatments for aids being explored in clinical trials?
Advancements in AIDS treatment continue to be explored through clinical trials, with several promising options on the horizon. One such treatment is MVA-BN-HIV, currently being tested in one active trial for AIDS. Another contender is alirocumab, also involved in one ongoing trial dedicated to treating this disease. Lastly, vedolizumab (branded as Entyvio) shows potential and has been listed since 2017 with one active and one all-time AIDS trial under its belt. As researchers tirelessly work towards finding effective solutions for those affected by AIDS, these treatments offer hope for improved outcomes and quality of life.
What are the most recent clinical trials for aids?
Promising advancements are being made in the field of AIDS research, with recent clinical trials offering hope for improved treatment options. One notable trial involves participants receiving DTG/3TC FDC for AIDS, a Phase 3 study that became available on July 7th, 2023. Similarly encouraging is the Phase 1 trial of 3BNC117-LS for AIDS, which was accessible from November 18th, 2022. Additionally, investigations into different approaches include Arm B: No anti-CMV treatment and A244/B.63521 + ALFQ adjuvant for AIDS in their respective phases. These trials exemplify our ongoing efforts to combat this challenging condition and bring us closer to finding effective interventions against HIV/AIDS.
What aids clinical trials were recently completed?
Recent clinical trials focusing on AIDS have showcased significant progress in the ongoing fight against this devastating disease. Notably, Janssen Research & Development completed a trial involving DRV/COBI FDC in August 2022. Other noteworthy studies include Tenofovir Douche trials conducted by Johns Hopkins University and the University of Pennsylvania, which concluded respectively in June 2021 and April 2021. The completion of these trials marks important milestones as researchers explore potential treatments for AIDS. These advancements offer hope for individuals affected by the disease and underscore the dedication of scientists working towards finding effective solutions to combat AIDS.